NCT06806917 Twenty Years' Experience in Retroperitoneal Lymph Node Dissection for Testicular Cancer in a Tertiary Referral Center
| NCT ID | NCT06806917 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| Condition | Testicular Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 65 participants |
| Start Date | 2021-12-01 |
| Primary Completion | 2026-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 65 participants in total. It began in 2021-12-01 with a primary completion date of 2026-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to evaluate the oncologic and functional outcomes of RPLND as primary treatment (stage I and IIA-IIB with negative markers) or of residual masses after chemotherapy (PC-RPLND) in the treatment of patients with seminomatous and non-seminomatous. In order to evaluate the role and the͛clinical impact of different surgical techniques of RPLND will be included patients treated with open, laparoscopic, and robot-assisted techniques
Eligibility Criteria
Inclusion Criteria: * Aged ≥ 18 years * RPLND of residual mass after chemotherapy in patient with testicular neoplasm seminomatous or nonseminomatous performed by open, laparoscopic, or robotic technique * Primary RPLND for seminomatous or nonseminomatous testicular neoplasm of stage I or IIA-IIB with negative markers performed with open, laparoscopic or robotic technique * RPLND performed by open, laparoscopic, or robotic technique for the treatment of tumors seminomatous or nonseminomatous chemiorefractory testicular tumors progressing after I and II line of chemotherapy * Acquisition of informed consent Exclusion criteria: * Patient with comorbidities with contraindication to surgery * Hemorrhagic diathesis RETROSPECTIVE PHASE. Patients with the same inclusion and exclusion criteria as in the prospective phase and already undergoing RPLND surgery with open, laparoscopic, or robotic technique from January 2000 to December 2020 in the͛framework of the normal course of care with a minimum follow-up of 12 months. (estimated to include approximately 120 patients).
Contact & Investigator
Eugenio Brunocilla, MD
PRINCIPAL INVESTIGATOR
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Frequently Asked Questions
Who can join the NCT06806917 clinical trial?
This trial is open to male participants only, studying Testicular Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06806917 currently recruiting?
Yes, NCT06806917 is actively recruiting participants. Contact the research team at angelo.mottaran2@unibo.it for enrollment information.
Where is the NCT06806917 trial being conducted?
This trial is being conducted at Bologna, Italy, Milan, Italy.
Who is sponsoring the NCT06806917 clinical trial?
NCT06806917 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. The principal investigator is Eugenio Brunocilla, MD at IRCCS Azienda Ospedaliero-Universitaria di Bologna. The trial plans to enroll 65 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.